Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369364 | 0.89 | CA2 (0.50) | CA2ATMEGFRHSD11B1ERBB2 | |
| SCHEMBL2443608 | 0.88 | CA2 (0.51) | CA2ATMEGFRHSD11B1ERBB2 | |
| SCHEMBL17364184 | 0.85 | ATM (0.45) | CA2ATMEGFRHSD11B1ERBB2 | |
| SCHEMBL28605173 | 0.81 | ATM (0.43) | ATMEGFRHSD11B1ERBB2KAT6A | |
| SCHEMBL263686 | 0.81 | ATM (0.46) | ATMKAT6AHSD17B2MMP2 | |
| SCHEMBL17699828 | 0.81 | ATM (0.43) | ATMEGFRHSD11B1ERBB2KAT6A | |
| SCHEMBL29782813 | 0.81 | ATM (0.43) | ATMEGFRHSD11B1ERBB2KAT6A | |
| SCHEMBL21872042 | 0.81 | ATM (0.61) | ATMEGFRHSD11B1ERBB2BRD4 | |
| SCHEMBL4251866 | 0.80 | PLCG1 (0.56) | ATMEGFRERBB2KAT6ABRD4 | |
| SCHEMBL2555899 | 0.80 | ATM (0.42) | ATMEGFRHSD11B1ERBB2KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| EP-2074086-B1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-09-23 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| EP-2074086-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008048609-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | CA2 804/4885ATM 3952/4885POLB 3046/4885 |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | CA2 2621/4885ATM 3595/4885POLB 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.